Incidence, etiology, and course of hypercalcemia-induced AKI in a tertiary care center from northern India

Nucksheeba Aziz Bhat¹, Farhat Mustafa², Rayees Yousuf Sheikh³* and Imtiyaz Wani⁴

Abstract

Background: Hypercalcemia is known to cause acute kidney injury (AKI). Literature related to hypercalcemic AKI is predominantly in the form of case reports and case series. The purpose of this study is to find the incidence, etiology, and course of hypercalcemia-induced AKI in a non-critical care setting. To our knowledge, this is the first study done to look for the incidence, etiology, and course of hypercalcemia-induced AKI in a non-critical care setting. This is a prospective observational study conducted in the Department of Medicine in a tertiary care center from Jammu and Kashmir, India, from June 2010 to June 2012. Patients admitted with hypercalcemia were assessed for AKI and evaluated and treated for hypercalcemia. Renal function was monitored during hospitalization and at 1 month of discharge. AKI and hypercalcemia were arbitrarily defined as serum creatinine > 1.5 mg/dl and corrected serum calcium of ≥11.5 mg/dl (as per reference hospital lab), respectively.

Results: Thirty patients are included. Hyperparathyroidism and multiple myeloma accounted for 13(43.3%) and 10 (33.3%) cases, respectively. Mean ±SD corrected serum calcium at diagnosis and after treatment at 1 month was 13.56 ± 1.86 mg/dl and 9.49±1.35 mg/dl, respectively; p < 0.001. Mean ±SD serum creatinine at baseline and after treatment of hypercalcemia was 2.87 ±1.68 mg/dl and 1.49±1.34 mg/dl, respectively; p < 0.001. Twenty-three (76.7%) patients had AKI. AKI recovered after treating hypercalcemia in 25 (83.3 %) patients. Mean ± SD days taken for the decrease in serum creatinine to ≤1.5 mg/dl was 8.28 ± 4.17 days. Mean ± SD serum creatinine after treatment of hypercalcemia in hyperparathyroidism group versus non-parathyroid group was 0.97 ± 0.35 mg/dl and 1.88 ±1.67 mg/dl, respectively; p value 0.009.

Conclusions: Hypercalcemia is commonly associated with AKI. Primary hyperparathyroidism and multiple myeloma account for the majority of the cases. Hypercalcemic AKI with primary hyperparathyroidism is less common and the outcome is better, as compared to non-hyperparathyroidism-related causes. AKI is reversible in most cases.

Keywords: Hypercalcemia, AKI, Primary hyperparathyroidism, Multiple myeloma

Background

Hypercalcemia is a relatively common clinically presenting problem with 90% of all cases accounted for by primary hyperparathyroidism and malignancy. The differential diagnosis of hypercalcemia consists of parathyroid hormone (PTH)-mediated hypercalcemia and non-PTH-mediated hypercalcemia. Causes of PTH-mediated hypercalcemia include primary hyperparathyroidism, familial hypocalciuric hypercalcemia, and ectopic PTH secretion. Causes of non-PTH-mediated hypercalcemia comprise vitamin D-mediated hypercalcemia (vitamin D intoxication, lymphoma, granulomatous diseases), vitamin A intoxication, hyperthyroidism, drug-induced hypercalcemia (hydrochlorothiazide, theophylline, and lithium), immobilization, milk-alkali syndrome, adrenal insufficiency, and humoral hypercalcemia of malignancy. Hypercalcemia is known to decrease the glomerular
filtration rate and cause acute kidney injury. Literature related to hypercalcemia-induced AKI is predominantly in the form of case reports and case series only. We sought to study the incidence, etiological profile, and course of hypercalcemia-induced AKI in a non-critical care center in northern India. To our knowledge, the present study is the first to describe the incidence, etiological profile, and course of hypercalcemia-induced AKI in a non-critical care setting.

Methods
This is a prospective observational study conducted in the Department of Medicine, in a tertiary care center from Jammu and Kashmir, India. The study was conducted from June 2010 till June 2012. All patients admitted with documented hypercalcemia were assessed for the presence of acute kidney injury and evaluated for the cause of hypercalcemia. AKI and hypercalcemia were arbitrarily defined as serum creatinine > 1.5 mg/dl (as per the upper limit of the reference hospital lab) and corrected serum calcium of ≥ 11.5 mg/dl (as per upper limit of the reference hospital lab) respectively. The patients were treated for hypercalcemia and renal function was monitored during the hospital stay and at 1 month of discharge. Serum creatinine was measured using the modified Jaffe kinetic method. Serum iPTH was estimated using solid-phase two-site chemiluminescent enzyme-labeled immunometric assay [1] and 25-OH Vit D was estimated using solid-phase ELISA [2]. All data are presented as mean ± SD. Dependent non-parametric data is analyzed by Wilcoxon’s matched-pair signed-rank test. Mann-Whitney U test is used for nonparametric independent data. The p value of < 0.05 is taken as significant. Statistical analysis is done using SPSS version 25.

Results
Thirty patients were included in the study. Men and women accounted for 11 (36.7%) and 19 (63.3%) of all the cases, respectively. The mean age at presentation was 50.87 ± 13.96 years. The most common presenting symptom was generalized weakness in 66.7% of patients followed by anorexia and bony pains in 56.7% and 46.7%, respectively. 23.3% of patients had pathological fractures. The symptoms were present in multiples. Primary hyperparathyroidism was the most common cause of hypercalcemia, followed by multiple myeloma, accounting for 13 (43.3%) and 10 (33.3%) of cases, respectively (Table 1). Mean ±SD corrected serum calcium at diagnosis and after treatment at 1 month was 13.56 ± 1.86 mg/dl and 9.49±1.35 mg/dl, respectively; p<0.001. Mean ± SD serum creatinine at baseline and after treatment of hypercalcemia at 1 month was 2.87 ± 1.68 mg/dl and 1.49 ± 1.34 mg/dl, respectively; p < 0.001 (Table 2).

| Etiology                  | No of patients (%) |
|---------------------------|--------------------|
| Primary hyperparathyroidism| 13 (43.3)          |
| Multiple myeloma          | 10 (33.3)          |
| Vit D toxicity            | 5 (16.7)           |
| Pulmonary tuberculosis    | 1 (3.3)            |
| Acute leukemia            | 1 (3.3)            |

Table 1 Etiological distribution of hypercalcemia

Twenty-three (76.7%) patients had AKI, defined as serum creatinine > 1.5 mg/dl. After treatment of hypercalcemia, serum creatinine decreased to ≤1.5 mg/dl in 25 (83.3%) patients. Mean ±SD days taken for the decrease in serum creatinine to ≤1.5 mg/dl was 8.28 ±4.17 days with a median of 7.50 days. AKI was seen in 10/10 (100%) patients with multiple myeloma and 6/13 (46.2%) patients with hyperparathyroidism. AKI resolved (decrease in serum creatinine to ≤1.5 mg/dl) after treatment of hypercalcemia in 5/6 (83.3%) and 8/10 (80%) cases of hyperparathyroidism and multiple myeloma, respectively. After treatment of hypercalcemia 92.3% of patients with primary hyperparathyroidism had normal renal functions. Serum creatinine decreased with the decrease in serum calcium in all but one patient. Primary hyperparathyroidism was due to parathyroid adenoma in 12/13 patients and parathyroid carcinoma in 1/13 patients. Mean ±SD serum calcium before treatment in the primary hyperparathyroidism group and the non-parathyroid group was 14.39 ±2.39 mg/dl and 12.97±1.15 mg/dl, respectively; p value 0.98. Mean ±SD serum calcium after treatment in the primary hyperparathyroidism group and the non-parathyroid group was 8.88±1.32 mg/dl and 9.98±1.22 mg/dl, respectively; p = 0.02. Mean ±SD serum creatinine before treatment in the primary hyperparathyroidism group and the non-parathyroid group was 2.04±1.58 mg/dl and 3.49±1.51 mg/dl respectively; (p<0.009). Mean ±SD serum creatinine after treatment in the hyperparathyroidism group and the non-parathyroid group was 0.97±0.35 mg/dl and 1.88±1.67 mg/dl, respectively; p 0.009. Results are summarized in Tables 3 and 4.

Discussion
Hypercalcemia is associated with acute kidney injury. The reversible decrease in glomerular filtration rate in severe hypercalcemia is thought to be mediated in part by direct renal vasoconstriction. This has been shown in a study comparing renal blood flow and glomerular filtration rates in hypercalcemic and normocalcemic rats [3]. Besides, a defect in urinary concentrating ability, leading to polyuria and polydipsia, results in volume depletion, contributing further to worsening of kidney function. This is thought to be due to the
downregulation of aquaporin 2 (AQP2) water channels in the collecting tubules [4] and tubulointerstitial injury caused by calcium deposition in the medulla [5]. In addition, activation of the calcium-sensing receptors present on the basolateral membrane of the thick ascending limb of the loop of Henle reduces calcium and sodium chloride reabsorption in the loop of Henle [6, 7].

AKI caused by hypercalcemia is usually reversible with volume expansion with saline solution and lowering of serum calcium concentration.

Our study enrolled 30 patients. The commonest presenting symptom was a generalized weakness in 66.7% of patients followed by anorexia and bony pain in 56.7% and 46.7%, respectively. Polyuria and constipation were present in 33.3% and 26.67% of patients, respectively. 23.3% of patients had pathological fractures. Mental changes in the form of irritability and confusion were seen in 10% of patients. The symptoms were present in multiples. The symptoms were non-specific, and in almost all, the diagnosis of hypercalcemia was not considered until the blood work revealed hypercalcemia.

Primary hyperparathyroidism is the most common cause of hypercalcemia in the community. It is caused by a single adenoma in about 85% of cases, with hyperplasia of all four parathyroids in 10% to 15% and with carcinoma in less than 2% [8]. In our study, also, primary hyperparathyroidism was the most common cause of hypercalcemia accounting for 43.3% of total cases. In 12/13 cases, primary hyperparathyroidism was due to solitary parathyroid adenoma. One of 13 patients had parathyroid carcinoma. In our study, 76.7% of patients developed AKI. A study done by Cyril Mousseaux et al. [9], showed hypercalcemia-associated AKI in 82.4% of cases. The median time taken for renal recovery was 10.5 days. In our study, all but one patient showed a decrease in serum creatinine following treatment of hypercalcemia. The patient had multiple myeloma as the cause of his hypercalcemia and possibly had paraproteinemia-related kidney disease as the predominant cause of renal dysfunction. The median time taken for renal recovery in our study was 7.50 days.

In patients with multiple myeloma-associated hypercalcemia, renal failure was seen in 100% of cases. A study on 56 patients with myeloma and severe renal failure identified hypercalcemia or a nonsteroidal anti-inflammatory agent as a potential precipitant of renal failure in 43% of the cases [11]. Incidence of AKI was less with primary hyperparathyroidism-related hypercalcemia as compared to non-hyperparathyroidism-related hypercalcemia. Similar findings were reported by Lins LE [12]. Furthermore, renal recovery was significantly better with hyperparathyroidism-related hypercalcemic AKI as compared with non-hyperparathyroidism-related hypercalcemic AKI. This is possible because most of the non-hyperparathyroidism-related AKI in our study were secondary to multiple myeloma and Vit-D toxicity. Patients with multiple myeloma have additional

### Table 2 Distribution of serum calcium and serum creatinine before and after treatment of hypercalcemia

|                        | Before treatment | After treatment | p value |
|------------------------|-----------------|----------------|---------|
| Corrected serum calcium mean ±SD (mg/dl) | 13.59 ±1.86 | 9.49 ±1.35 | < 0.001 |
| Serum creatinine mean ±SD (mg/dl) | 2.87 ±1.68 | 1.49 ±1.34 | < 0.001 |

### Table 3 Distribution of diagnosis with renal function before and after treatment of hypercalcemia

| Etiology                        | Before treatment creatinine ≤1.5 mg/dl | Before treatment creatinine > 1.5 mg/dl | After treatment creatinine ≤1.5 mg/dl | After treatment creatinine > 1.5 mg/dl |
|---------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|----------------------------------------|
|                                 | 7/30 (23.3)                            | 23/30 (76.7)                            | 25/30 (83.3)                            | 5/30 (16.7)                            |
| Primary hyperparathyroidism     | 7 (53.8%)                              | 6 (46.2)                                | 12 (92.3)                               | 1 (7.7)                                |
| Multiple myeloma                | 0                                      | 10 (100)                                | 8 (80)                                  | 2 (20)                                 |
| Vit D toxicity                  | 0                                      | 5 (100)                                 | 3 (60)                                  | 2 (40)                                 |
| Pulmonary tuberculosis          | 0                                      | 1 (100)                                 | 1 (100)                                 | 0                                      |
| Acute leukemia                  | 0                                      | 1 (100)                                 | 1 (100)                                 | 0                                      |
| Total                           | 7/30 (23.3)                            | 23/30 (76.7)                            | 25/30 (83.3)                            | 5/30 (16.7)                            |

Figures in parenthesis represent the percentage.
mechanisms in the form of paraproteinemia-related kidney disease, NSAID use, and susceptibility to infections, in addition to hypercalcemia that might give rise to renal dysfunction. Patients with Vit D toxicity invariably have NSAID exposure for chronic pains and aches which increases the risk for hypercalcemia-induced AKI. All patients with primary hyperparathyroidism in our study underwent surgical intervention with rapid and sustained correction of serum calcium which might be the reason for a better outcome of AKI in primary hyperparathyroidism. Treatment for hypercalcemia was directed based on the etiology of hypercalcemia. All patients in our study received 0.9% saline infusion. The rate of infusion was based on the hydration status of the patient and the 24-h fluid balance, to avoid the risk of volume overload in patients with advanced renal dysfunction. All 13 patients with primary hyperparathyroidism underwent parathyroidectomy. Vitamin D supplements were stopped in all patients with proven vitamin D toxicity. Three patients with Vit-D toxicity-related hypercalcemia received steroids, and one patient received zoledronic acid (modified dose) in addition to normal saline infusion and steroids. Steroids were given in the form of oral prednisolone at the dose of 1 mg/kg body-weight for 4 weeks and were subsequently tapered over the next 4 weeks. All patients receiving steroids were given septran prophylaxis. Four of 10 patients with multiple myeloma received chemotherapy. Five of 10 received modified dose zoledronic acid infusion. Zoledronic acid was given at the dose of 2 mg diluted in 100 cc of normal saline slowly iv over 2 h. Patient with pulmonary tuberculosis received normal saline infusion and was started on modified dose antitubercular treatment. A patient with acute leukemia was initiated on chemotherapy.

There are certain limitations to this study. First, the number of patients included in the study is small. Second, we do not have any follow-up of patients beyond 1 month. Third, we don’t have kidney biopsy data to determine the cause of persistent renal dysfunction in 5 patients. A bigger study would be required to confirm the findings of our study.

Table 4 Distribution of serum calcium and serum creatinine before and after treatment in the hyperparathyroid and non-hyperparathyroid group

| Parameter                                      | Hyperparathyroidism | Non-hyper-parathyroid related | P value |
|------------------------------------------------|---------------------|-------------------------------|---------|
| Corrected serum calcium mean ±SD (mg/dl) before treatment | 14.39 ± 2.39        | 12.97 ± 1.15                 | 0.98    |
| Corrected serum calcium mean ±SD (mg/dl) after treatment  | 8.88 ± 1.32         | 9.98 ± 1.22                  | 0.02    |
| Serum creatinine mean ±SD (mg/dl) before treatment       | 2.04 ± 1.58         | 3.49 ± 1.51                  | 0.009   |
| Serum creatinine mean ±SD (mg/dl) after treatment        | 0.97 ±0.35          | 1.88 ± 1.67                  | 0.009   |

Conclusions
Hypercalcemia is commonly associated with AKI. Primary hyperparathyroidism and multiple myeloma account for the majority of cases. Hypercalcemic AKI with primary hyperparathyroidism is less common and the outcome is better, as compared to non-hyperparathyroidism-related causes. AKI is reversible in most cases.

Abbreviations
AKI: Acute kidney injury

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s43162-021-00067-8.

Acknowledgements
Dr. Abdul Rashid Reshi, Professor of Nephrology for his guidance during the conduct of the study.

Authors’ contributions
NA, FM, RS, and IW contributed to the design and development of the study. NA, FM, and RS contributed to data collection. NA, FM, RS, and IW contributed data analysis and interpretation. NA, FM, RS participated in the writing of the manuscript. RS and IW participated in the critical review. NA, FM, RS, and IW provided approval for the final manuscript.

Funding
The study is not funded.

Availability of data and materials
The data and material would be made available on request.

Declarations
Ethics approval and consent to participate
The study is approved by SKIMS institutional ethics committee on 6th May 2010. Since this is an observational study wherein the study participants received standard treatment protocol, the consent to participate was waived off by the SKIMS institutional ethics committee.

Consent for publication
Not applicable

Competing interests
There are no conflicts of interest.

Author details
1Government Medical College, Department of Pediatrics, GB Pant Cantonment Hospital, Srinagar, India. 2Government Medical College,
Department of Medicine, SMHS Hospital, Srinagar, India. 1Department of Nephrology, Bahrain Specialist Hospital, Manama, Bahrain. 2Sheri-Kashmir Institute of Medical Sciences, Srinagar, India.

Received: 13 March 2021 Accepted: 18 April 2021
Published online: 02 November 2021

References
1. Girish P, Lala M, Chadha M, Shah NF, Chauhan PH (2012) Study of primary hyperparathyroidism. Indian J Endocrinol Metab 16(Suppl 2):S418–S520. https://doi.org/10.4103/2230-8210.104114
2. He CS, Gleeson M, Fraser WD (2013) Measurement of circulating 25-Hydroxy Vitamin D Using Three Commercial Enzyme-Linked Immunosorbent assay Kits with Comparison to Liquid chromatography. ISRN NutrTandem Mass Spectrometry Meth 723139:1–6. https://doi.org/10.5402/2013/723139
3. Levi M, Ellis MA, Berl T (1983) Control of renal hemodynamics and glomerular filtration rate in chronic hypercalcaemia: Role of prostaglandins, renin-angiotensin system, and calcium. J Clin Invest 71(6):1624–1632. https://doi.org/10.1172/JCI110918
4. Earn JH, Christensen BM, Frokiaer J et al (1998) Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 9(12):2181–2193. https://doi.org/10.1681/ASN.V912181
5. Rosen S, Greenfield Z, Berheim J, Rathaus M, Podjarny E, Brezis M (1990) Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury. Kidney Int 37(4):1067–1075. https://doi.org/10.1038/ki.1990.87
6. Hebert SC (1996) Extracellular calcium sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 50(6):2129–2139. https://doi.org/10.1038/kl.1996.33
7. Peterson LN, McKay AJ, Borzecki JS (1993) Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcaemia. J Clin Invest 91(6):2399–2407. https://doi.org/10.1172/JCI116473
8. Martin TJ, Grill V (1995) Hypercalcaemia. Clin Endocrinol 42(5):535–538. https://doi.org/10.1111/j.1365-2265.1995.tb02674.x
9. Moudeaux C, Dupont A, Rafat C, Elpe K, Ghenassia E, Kerhuel L, Ardisson F, Mariotte E, Lemsale V, Schlemmer B, Azoulay E, Zafra L (2019) Epidemiology, clinical features, and management of severe hypercalcaemia in critically ill patients. Ann Intensive Care 9(1):133. https://doi.org/10.1186/s13613-019-0606-8
10. Moyés-Neto M, Guimarães FM, Ayoub FH, Vieira-Neto OM, Costa JAC, Dantas M (2006) Acute Renal Failure and Hypercalcaemia. Ren Fail 28(2):153–159. https://doi.org/10.1080/0886020050031005
11. Irish AB, Winears CG, Littlewood T (1997) Presentation and survival of patients with severe renal failure and myeloma. QJM. 90(12):773–780. https://doi.org/10.1093/qjmed/90.12.773
12. Lins LE (1978) Reversible renal failure caused by hypercalcaemia. A retrospective study. Acta Med Scand 203(4):309–314. https://doi.org/10.1111/j.0954-6820.1978.tb14879x

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.